Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

PHASE1RecruitingINTERVENTIONAL
Enrollment

614

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

May 29, 2026

Study Completion Date

June 30, 2026

Conditions
Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors
Interventions
DRUG

RMC-6236

Oral Tablets

Trial Locations (16)

10016

RECRUITING

Perlmutter Cancer Center at NYU Langone Health, New York

10021

RECRUITING

Memorial Sloan-Kettering Cancer Center, New York

10032

RECRUITING

Columbia University, New York

21287

RECRUITING

Johns Hopkins University, Baltimore

22031

RECRUITING

Next Oncology Virginia, Fairfax

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

45219

RECRUITING

Christ Hospital Cancer Center, Cincinnati

75230

RECRUITING

Mary Crowley Cancer Research, Dallas

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

78229

RECRUITING

Next Oncology, San Antonio

78712

RECRUITING

University of Texas at Austin, Austin

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

90404

RECRUITING

UCLA, Santa Monica

92868

RECRUITING

UC Irvine/Chao Family Comprehensive Cancer Center, Orange

02215

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Revolution Medicines, Inc.

INDUSTRY